Moyamoya Disease and Syndrome in Children

Status: draft · Last updated 2026-11-03 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Disease vs syndrome: idiopathic disease vs association with NF1, Down syndrome, radiation or sickle cell. Syndromes can be aggressive in young children .
  • It progresses: 18–59% of unilateral pediatric cases become bilateral, mostly within 3 years, with faster progression in younger children .
  • Surgery beats conservative care for symptomatic children (stroke OR 0.33) .
  • Indirect vs direct or combined: similar clinical outcomes in children, better angiographic filling with combined, and more wound complications with direct .
  • Pial synangiosis: about 4% stroke per hemisphere at 30 days, then durable protection .
  • Perioperative: keep children well hydrated and normotensive, avoid crying and hyperventilation, continue aspirin, and watch Hb drops. The youngest children and those with recent TIAs are at highest risk .
  • Long-term surveillance: watch for late hemorrhage, especially after cranial radiation .

Landmark papers

  • Pial synangiosis (Scott et al., J Neurosurg 2004): 143 patients 21 or younger (271 craniotomies). The 30-day stroke rate was 7.7% per patient (4% per hemisphere), and only 4 of 126 children followed beyond 1 year had a late stroke .
  • Japan Adult Moyamoya trial (Miyamoto et al., Stroke 2014): in hemorrhagic moyamoya, mostly adults, direct bypass reduced rebleeding (2.7% vs 7.6% per year) .
  • ESO guideline (Bersano et al., Eur Stroke J 2023): suggests direct or combined over indirect bypass in children with hemodynamic impairment, and surgery 6–12 weeks after the last cerebrovascular event .

Moyamoya is a progressive narrowing of the terminal internal carotid arteries and their proximal branches, with a fragile network of basal collaterals (the angiographic "puff of smoke").

Children usually present with ischemia: transient ischemic attacks (TIAs) and strokes. Surgical revascularization is the mainstay of treatment.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:moyamoya:fcd49a7a296193fb© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Top: frontal angiographic view of moyamoya with stenosis of the terminal internal carotid arteries, attenuated anterior and middle cerebral arteries and a basal puff-of-smoke collateral network. Bottom: pial synangiosis, lateral view, with the superficial temporal artery rising in front of the ear and laid through a craniotomy onto the pial surfaceMOYAMOYA, FRONTAL (AP) VIEW"puff of smoke"basal collateralsstenosedterminal ICAattenuatedMCAfaint ACARLPIAL SYNANGIOSIS, LATERAL VIEWcraniotomy:dura andarachnoidopenedSTA suturedto the piaSTA rising infront of the earearnot to scale
Top: frontal (AP) angiographic view of moyamoya, with stenosis of the terminal ICAs, attenuated MCA and ACA, and a basal collateral network. Bottom: indirect revascularization by pial synangiosis (lateral view), with the superficial temporal artery (STA) laid through a craniotomy and sutured to the pial surface, where new collaterals grow over months. Not to scale.

Who gets it: disease vs syndrome

Natural history

Evaluation

Treatment

Perioperative care (high-risk window)

Related topics

References

  1. Phi JH, Wang KC, Lee JY, et al. Moyamoya syndrome: a window of moyamoya disease. J Korean Neurosurg Soc 2015;57(6):408–414. doi:10.3340/jkns.2015.57.6.408. PMID 26180607. verified
  2. Scott RM, Smith JL, Robertson RL, et al. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 2004;100(2 Suppl Pediatrics):142–149. doi:10.3171/ped.2004.100.2.0142. PMID 14758941. verified
  3. Brosius SN, Vossough A, Fisher MJ, et al. Characteristics of moyamoya syndrome in pediatric patients with neurofibromatosis type 1. Pediatr Neurol 2022;134:85–92. doi:10.1016/j.pediatrneurol.2022.05.013. PMID 35849956. verified
  4. See AP, Ropper AE, Underberg DL, et al. Down syndrome and moyamoya: clinical presentation and surgical management. J Neurosurg Pediatr 2015;16(1):58–63. doi:10.3171/2014.12.PEDS14563. PMID 25837890. verified
  5. Scala M, Fiaschi P, Cama A, et al. Radiation-induced moyamoya syndrome in children with brain tumors: case series and literature review. World Neurosurg 2020;135:118–129. doi:10.1016/j.wneu.2019.11.155. PMID 31805403. verified
  6. Aldana PR, Hanel RA, Piatt J, et al. Cerebral revascularization surgery reduces cerebrovascular events in children with sickle cell disease and moyamoya syndrome: results of the stroke in sickle cell revascularization surgery retrospective study. Pediatr Blood Cancer 2023;70(7):e30336. doi:10.1002/pbc.30336. PMID 37057741. verified
  7. Park EK, Lee YH, Shim KW, et al. Natural history and progression factors of unilateral moyamoya disease in pediatric patients. Childs Nerv Syst 2011;27(8):1281–1287. doi:10.1007/s00381-011-1469-y. PMID 21552998. verified
  8. Yeon JY, Shin HJ, Kong DS, et al. The prediction of contralateral progression in children and adolescents with unilateral moyamoya disease. Stroke 2011;42(10):2973–2976. doi:10.1161/STROKEAHA.111.622522. PMID 21836096. verified
  9. Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 2008;24(2):E17. doi:10.3171/FOC/2008/24/2/E17. PMID 18275294. verified
  10. Shahbandi A, Sattari SA, Azad TD, et al. The management of symptomatic moyamoya disease in pediatric patients: a systematic review and meta-analysis. Neurosurgery 2024;97(1):65–81. doi:10.1227/neu.0000000000003277. PMID 39560368. verified
  11. Hayashi T, Hara S, Inaji M, et al. Long-term prognosis of 452 moyamoya disease patients with and without revascularization under perfusion-based indications. J Stroke Cerebrovasc Dis 2023;32(11):107389. doi:10.1016/j.jstrokecerebrovasdis.2023.107389. PMID 37778161. verified
  12. Kuroda S, Yamamoto S, Funaki T, et al. Five-year stroke risk and its predictors in asymptomatic moyamoya disease: Asymptomatic Moyamoya Registry (AMORE). Stroke 2023;54(6):1494–1504. doi:10.1161/STROKEAHA.122.041932. PMID 37216455. verified
  13. Kuroda S, Yamamoto S, Funaki T, et al. Disease progression, transient ischemic attack, and de novo parenchymal lesions in asymptomatic moyamoya disease: results of a 5-year interim analysis of the AMORE study. J Neurosurg 2025;142(3):658–666. doi:10.3171/2024.6.JNS24736. PMID 40367646. verified
  14. Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 2014;45(5):1415–1421. doi:10.1161/STROKEAHA.113.004386. PMID 24668203. verified
  15. Bersano A, Khan N, Fuentes B, et al. European Stroke Organisation (ESO) guidelines on moyamoya angiopathy endorsed by Vascular European Reference Network (VASCERN). Eur Stroke J 2023;8(1):55–84. doi:10.1177/23969873221144089. PMID 37021176. verified
  16. Jackson EM, Lin N, Manjila S, et al. Pial synangiosis in patients with moyamoya younger than 2 years of age. J Neurosurg Pediatr 2014;13(4):420–425. doi:10.3171/2014.1.PEDS13251. PMID 24527861. verified
  17. Lee KS, Zhang JJY, Bhate S, et al. Surgical revascularizations for pediatric moyamoya: a systematic review, meta-analysis, and meta-regression analysis. Childs Nerv Syst 2023;39(5):1225–1243. doi:10.1007/s00381-023-05868-6. PMID 36752913. verified
  18. Karsten MB, Smith ER, Scott RM. Late morbidity and mortality following revascularization surgery for moyamoya disease in the pediatric population. J Neurosurg Pediatr 2021;28(2):206–211. doi:10.3171/2021.1.PEDS20944. PMID 34116511. verified
  19. Gardner Yelton SE, Gatti J, Adil M, et al. Risk factors and imaging biomarkers associated with perioperative stroke in pediatric moyamoya arteriopathy. J Child Neurol 2022;37(12-14):963–969. doi:10.1177/08830738221125554. PMID 36128779. verified
  20. Gatti JR, Ahmad SA, Gardner Yelton S, et al. Relative anemia and perioperative stroke in children with moyamoya. J Stroke Cerebrovasc Dis 2024;33(1):107476. doi:10.1016/j.jstrokecerebrovasdis.2023.107476. PMID 37976795. verified
  21. Sun LR, Jordan LC, Smith ER, et al. Pediatric moyamoya revascularization perioperative care: a modified Delphi study. Neurocrit Care 2024;40(2):587–602. doi:10.1007/s12028-023-01788-0. PMID 37470933. verified

Verification (2026-11-03): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. Full texts were not reviewed. References 12–14 are adult studies, included for context. Reference 11 mixes adults and children; only its pediatric findings are used for children. The description of indirect and direct techniques, the imaging work-up details beyond reference 15, avoiding dehydration and hypotension, and the effect of crying and hyperventilation on CO₂ are standard teaching given without a citation. The 18–59% range for contralateral progression spans references 7–9, which differ in design and follow-up. The schematics are original figures.